Grifols SA reported a strong 7.4% revenue increase in Q1 2025, reaching EUR 1,786 million, with an adjusted EBITDA rise of 14.2% to EUR 400 million, driven by strong Biopharma performance. The results were reported on May 12, 2025, highlighting a 179% year-over-year profit growth of EUR 60 million.